HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DOTA-4D5

Also Known As:

111In-DOTA-4D5; DOTA-anti-HER2 neu antibody 4D5

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Raubitschek, A A: 1 article (05/2000)
2.	Shively, J E: 1 article (05/2000)
3.	Sun, Y: 1 article (05/2000)
4.	Tsai, S W: 1 article (05/2000)
5.	Williams, L E: 1 article (05/2000)
6.	Wu, A M: 1 article (05/2000)

Related Diseases

1.

Neoplasms (Cancer)

05/01/2000 - "Treatment with unlabeled DOTA-4D5 (3 microg) had a slight effect on tumor growth compared to untreated controls. "
05/01/2000 - "For the biodistribution of (111)In-labeled DOTA-4D5, a high specificity of tumor localization (30% ID/g) was seen with a tumor-to-blood ratio of greater than 2 at 48 h postinjection. "
05/01/2000 - "Although a cold antibody therapeutic effect was unexpected at this dose level (3 microg), it may be possible that in some animals that 3 microg of antibody of (90)Y-labeled DOTA-4D5 augmented tumor growth reduction. "
05/01/2000 - "In the therapy study, treatment of the nude mice bearing MCF7/HER2/neu xenografts with 100 microCi (3 microg) of (90)Y-labeled DOTA-4D5 caused a 3-fold reduction of tumor growth compared to untreated controls (injected with human serum albumin) in 40 days. "

Related Drugs and Biologics

1.	Human Serum Albumin
2.	Therapeutic Uses

Related Therapies and Procedures

1.	Therapeutics